Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Horwitz
    Horwitz
  2. Sadelain
    Sadelain
  3. Arcila
    Arcila
  4. Levine
    Levine
  5. O'Reilly
    O'Reilly
  6. Wolden
    Wolden
  7. Abdel-Wahab
    Abdel-Wahab
  8. Castro-Malaspina
    Castro-Malaspina
  9. Giralt
    Giralt
  10. Zelenetz
    Zelenetz

Groups

  1. Center for Hematologic Malignancies (257)
  2. Department of Medicine (214)
  3. Hematologic Malignancies, Division of (208)
  4. GSK Faculty (93)
  5. Adult Leukemia (67)
  6. Sloan Kettering Institute Faculty (63)
  7. Lymphoma (56)
  8. Executive Committee, Center for Hematologic Malignancies (52)
  9. Bone Marrow Transplant (51)
  10. Tow Center for Developmental Oncology (TCDO) (50)
Search Within
  1. "Center for Hematologic Malignancies"
Formats
  1. Journal Article (138)
  2. Meeting Abstract (99)
  3. Review (13)
  4. Correspondence (2)
  5. Editorial (2)
  6. Guidelines (2)
  7. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (257)
  2. Department of Medicine (214)
  3. Hematologic Malignancies, Division of (208)
  4. GSK Faculty (93)
  5. Adult Leukemia (67)
  6. Sloan Kettering Institute Faculty (63)

More Groups

People
  1. Steven Horwitz (18)
  2. Michel Sadelain (16)
  3. Maria Arcila (13)
  4. Richard O'Reilly (12)
  5. Ross Levine (12)
  6. Suzanne Wolden (12)

More People

Years
  1. 2025 (2)
  2. 2024 (16)
  3. 2023 (15)
  4. 2022 (11)
  5. 2021 (17)
  6. 2020 (26)

More Years

Publications
  1. Experimental Hematology (56)
  2. Lancet Oncology (34)
  3. The Lancet Haematology (31)
  4. Journal of Molecular Diagnostics (23)
  5. Value in Health (20)
  6. Lancet (13)

More Publications

Results (257)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clonal characterization and somatic hypermutation assessment by next-generation sequencing in chronic lymphocytic leukemia/small lymphocytic lymphoma: A detailed description of the technical performance, clinical utility, and platform comparison
    Journal Article

    Petrova-Drus, K.; Syed, M.; Yu, W.; Hutt, K.; Zlotnicki, A. M.; Huang, Y.; Kamalska-Cyganik, M.; Maciag, L.; Wang, M.; Ma, Y. G.; more...
    Journal of Molecular Diagnostics (2023)

    Fulltext@MSK | Save
  • Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: A phase 1, dose-finding and expansion study
    Journal Article

    Garcia-Manero, G.; Goldberg, A. D.; Winer, E. S.; Altman, J. K.; Fathi, A. T.; Odenike, O.; Roboz, G. J.; Sweet, K.; Miller, C.; Wennborg, A.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Final results of a phase I trial of WST-11 (TOOKAD Soluble) vascular-targeted photodynamic therapy for upper tract urothelial carcinoma
    Journal Article

    Yip, W.; Sjoberg, D. D.; Nogueira, L. M.; Tracey, A. T.; Alvim, R. G.; Reisz, P. A.; Demac, Q.; Benfante, N. E.; Vanden Berg, R. W.; Kim, K.; more...
    Journal of Urology (2023)

    Fulltext@MSK | Save
  • Health care resource utilization with asciminib and bosutinib among adults with chronic myeloid leukemia in chronic phase previously treated with ≥2 tyrosine kinase inhibitors: Week 48 and week 96 results from ASCEMBL trial
    Meeting Abstract

    Cortes, J. E.; Sasaki, K.; Réa, D.; Mauro, M. J.; Tran, D.; Wang, P.; Jadhav, K.; Di Caprio, L.; Yocolly, A.
    Value in Health (2022)

    Fulltext@MSK | Save
  • A matching-adjusted indirect comparison of asciminib versus ponatinib, nilotinib and dasatinib in chronic phase chronic myeloid leukemia patients after ≥2 tyrosine kinase inhibitors
    Meeting Abstract

    Atallah, E. L.; Maheshwari, V.; Mauro, M. J.; Boquimpani, C.; Rea, D.; Hochhaus, A.; Minami, Y.; Saini, L.; Corbin, R.
    Value in Health (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) from the informCLL registry: A prospective, multicenter, observational study of US patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Cll/Sll)
    Meeting Abstract

    Sharman, J.; Barrientos, J. C.; Ghosh, N.; Brander, D.; Gutierrez, M.; Wu, L.; Panjabi, S.; Upasani, S.; Jermain, M.; Naganuma, M.; more...
    Value in Health (2022)

    Fulltext@MSK | Save
  • PI3K inhibitors in haematological malignancies
    Correspondence

    Matasar, M. J.; Hiemeyer, F.; Childs, B. H.; Zinzani, P. L.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Predictors of major hemorrhage after spleen core biopsy in cancer patients
    Journal Article

    Kunin, H.; Wijetunga, N. A.; Erinjeri, J. P.; Noy, A.; Deipolyi, A. R.
    Journal of Vascular and Interventional Radiology (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study
    Journal Article

    Budde, L. E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: A multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
    Journal Article

    Pagel, J. M.; Soumerai, J. D.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A.; Salman, H.; Kenkre, V. P.; Iasonos, A.; Llorin-Sangalang, J.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save